Exelixis/$EXEL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Exelixis
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Ticker
$EXEL
Sector
Primary listing
Employees
1,077
Headquarters
Website
Exelixis Metrics
BasicAdvanced
$13bn
17.17
$3.02
0.38
-
Price and volume
Market cap
$13bn
Beta
0.38
52-week high
$53.93
52-week low
$33.76
Average daily volume
2.6m
Financial strength
Current ratio
3.258
Quick ratio
3.01
Long term debt to equity
8.758
Total debt to equity
8.758
Profitability
EBITDA (TTM)
985.841
Gross margin (TTM)
96.44%
Net profit margin (TTM)
35.08%
Operating margin (TTM)
40.29%
Effective tax rate (TTM)
16.92%
Revenue per employee (TTM)
$2,210,000
Management effectiveness
Return on assets (TTM)
22.03%
Return on equity (TTM)
40.99%
Valuation
Price to earnings (TTM)
17.173
Price to revenue (TTM)
5.823
Price to book
6.8
Price to tangible book (TTM)
7.03
Price to free cash flow (TTM)
15.28
Free cash flow yield (TTM)
6.54%
Free cash flow per share (TTM)
3.397
Growth
Revenue change (TTM)
3.33%
Earnings per share change (TTM)
37.17%
3-year revenue growth (CAGR)
12.60%
10-year revenue growth (CAGR)
49.28%
3-year earnings per share growth (CAGR)
85.92%
10-year earnings per share growth (CAGR)
13.45%
What the Analysts think about Exelixis
Analyst ratings (Buy, Hold, Sell) for Exelixis stock.
Exelixis Financial Performance
Revenues and expenses
Exelixis Earnings Performance
Company profitability
Exelixis News
AllArticlesVideos
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
Business Wire·3 weeks ago
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June
Business Wire·3 weeks ago
Caring Men Global Partners with Exelixis to Launch “Strong Caregivers, Stronger Survivors” Caregiver Training Initiative
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs